The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development

Future Medicinal Chemistry

Volumn 2, Issue 6, 2010, Pages 923-928

  Yu, Xiang Qing ^a   Wilson, Alan Ge ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

BIOTRANSFORMATION; COMPUTER MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SOLUBILITY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; MICRODOSIMETRY; NOTE; PHARMACODYNAMICS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SYSTEMS BIOLOGY;

ANIMALS; COMPUTER SIMULATION; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 77953628468     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.181     Document Type: Note

References (42)

1. van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2(3), 192-204 (2003).
2. Ekins S, Waller CI, Swaan PW, Cruciani G, Wrighton SA, Wikel JH. Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods 44(1), 251-272 (2000).
3. Wilson AGE, White AC, Mueller RA. Role of predictive metabolism and toxicity modeling in drug discovery - a summary of some recent advancements. Curr. Opin. Drug Discov. Devel. 6(1), 123-128 (2003).
4. Obach RS, Baxter JG, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283(1), 46-58 (1997).
5. Ito K, Houston JB. Comparison of the use of the liver models for predicting drug clearance using in vitro kinetics data from hepatic microsomes and isolated hepatocytes. Pharm. Res. 21(5), 785-792 (2004).
6. Iwatsubo T, Hirota N, Ooie T et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73(2), 147-171 (1997).
7. Andersson TB, Bredberg E, Ericsson H, Sjoberg H. An evaluation of the in vitro metabolism data for prediction the clearance and drug- drug interaction potential of CYP2C9 substrates. Drug Metab. Dispos. 32(7), 715-721 (2004).
8. Sarawek S, Li L, Yu XQ et al. Examination of the utility of the high-throughput in vitro metabolic stability assay to estimate in vivo clearance in the mouse. Open Drug Metab. J. 3, 31-42 (2009).
9. Soars M, Webborn PJH, Riley RJ. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol. Pharm. 6(6), 1662-1677 (2009).
10. Mahmood I. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv. Drug Deliv. Rev. 59(11), 1177-1192 (2007).
11. Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lavé T. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J. Pharm. Sci. 92(10), 1990-2007 (2003).
12. Jones HM, Gardner IB, Waston KJ. Modeling and PBPK simulation in drug discovery. AAPS J. 11(1), 155-166 (2009).
13. Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45(5), 511-542 (2006).
14. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10(7), 1093-1095 (1993).
15. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13(4),407-484 (1997).
16. Schmitt W, Willmann S. Physiology-based pharmacokinetic modeling: ready to be used. Drug Discov. Today Technol. 1(4), 449-456 (2004).
17. Fang L, Sun D. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy. Drug Metab. Dispos. 36(6), 1153-1165 (2008).
18. Kummar S, Kinders R, Rubinstein L et al. Compressing drug development timelines in oncology using phase '0' trials. Nat. Rev. Cancer 7(2), 131-139 (2007).
19. LoRusso PM. Phase 0 clinical trials: an answer to drug development stagnation? J. Clin. Oncol. 27(16), 2586-2588 (2009).
20. Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br. J. Cancer 97(5), 577-581 (2007).
21. Sheiner LB, Steimer JL. Pharmacokinetic/ pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 40, 67-95 (2000).
22. Uchizono JA, Lane JR. Emprircal pharmacokinetic/pharmacodynamic models. In: Pharmacometrics. Ette I, Williams PJ (Eds). John Wiley & Son Inc., Hoboken, NJ, USA, 529-546 (2007).
23. Dokoumetzidis A, Iliadis A, Macheras P. Nonlinear dynamics in clinical pharmacology: the paradigm of cortisol secretion and suppression. Br. J. Clin. Pharmacol. 54(1), 21-29 (2002).
24. Rohatagi S, Carrothers TJ, Kuwabara-Wagg J, Khariton T. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating QTc prolongation potential of drugs. J. Clin. Pharmacol. 49(11), 1284-1296 (2009).
25. Yao Z, Dubois DC, Almon RR, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. J. Pharm. Sci. 97(7), 2820-2832 (2008).
26. Overgaard RV, Holford N, Rytved KA, Madsen H. PKPD model of interleukin-21 effects on thermoregulation in monkeys-application and evaluation of stochastic differential equations. Pharm. Res. 24(2), 298-309 (2007).
27. Yamasaki Y, Tiran J, Albisser AM. Modeling glucose disposal in diabetic dogs fed mixed meals. Am. J. Physiol. 246(1 Pt 1), E52-E61 (1984).
28. Ashford JW, Schmitt FA. Modeling the time-course of Alzheimer dementia. Curr. Psychiatry Rep. 3(1), 20-28 (2001).
29. Simeoni M, Magni P, Cammia C et al. Predictive pharmacokinetic- pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 64(3), 1094-1101 (2004).
30. Danhof M, de Jongh J, De Lange E, Pasqua OD, Ploeger BA, Voskuy RA. Mechanism-based pharmacokinetic- pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47, 357-400 (2007).
31. Yu XQ, Kramer J, Moran L et al. PK/PD modeling of 2-acetyl-4(5)- tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid S1P. Xenobiotica 40(5), 350-356 (2010).
32. Beier H, Garrido MJ, Christoph T, Kasel D, Troconiz IF. Semi-mechanistisc pharmacokinetic/pharmacodynamic modelling of the anticociceptive response in the presence of competitive antagonism: the interaction between tramadol and its active metabolite on ?-opioid agonism and monoamine reuptake inhibition, in the rat. Pharm. Res. 25(8), 1789-1797 (2008).
33. Gupta P, Friberg LE, Karlsson MO, Krishnaswami S, French J. A mini-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rhenmatoid arthritis. J. Clin. Pharmacol. (2009)(Epub ahead of print).
34. Jonsson EN, Macintyre F, James I, Krams M, Marshall S. Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition. Pharm. Res. 22(8), 1236-1246 (2005).
35. Biomarkers Definitions Working Group. Biomarker and surrogate end points: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
36. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2(7), 566-580 (2003).
37. Colburn WA. Biomarkers in drug discovery and development: from target identification through drug marketing. J. Clin. Pharmacol. 43(4), 329-341 (2003).
38. Krishna R, Herman G, Wagner JA. Accelerating drug development using biomarkers: a case study with Sitagliptin, a novel DPP4 inhibitor for Type 2 diabetes. AAPS J. 10(2), 401-409 (2008).
39. Davidov E, Holland J, Marple E, Naylor S. Advancing drug discovery through systems biology. Drug Discov. Today 8(4), 175-183 (2003).
40. Krishna R, Schaefer HG, Bjerrum O. Effective integration of systems biology, biomarkers, biosimulation, and modeling in streamlining drug development. J. Clin. Pharmacol. 47(6), 738-743 (2007). (Pubitemid 46800416)
41. Zhang L, Sinha V, Forgue T et al. Model-based drug development: the road to quantitative pharmacology. J. Pharmacokinet. Pharmacodyn. 33(3), 369-393 (2006).
42. Gobburu J, Marroum PJ. Utilisation of pharmacokinetic-pharmacodynamic modeling and simulation in regulatory decision-making. Clin. Pharmacokinet. 40(12), 883-892 (2001).